Agenda & Speakers

09 JUL
Optimizing Therapy for Patients of Radioiodine-Refractory Differentiated Thyroid Cancer


9 July 2024

8:00pm - 9:00pm (GMT+9)

Session 1: When Should We Initiate Lenvatinib to Maximize Its Efficacy?
Dr. Naoki Fukuda
Dr. Naoki Fukuda
Japanese Foundation for Cancer Research, Japan
Session 2: Safety Management in the Treatment of Radioiodine-Refractory DTC
Dr. Kenneth Wong
Dr. Kenneth Wong
Prince of Wales Hospital, Hong Kong
Panel Discussion
Dr. Marcia Brose
Dr. Marcia Brose
Sidney Kimmel Medical College, Thomas Jefferson University
Dr. Naoki Fukuda
Dr. Naoki Fukuda
Japanese Foundation for Cancer Research, Japan
Dr. Kenneth Wong
Dr. Kenneth Wong
Prince of Wales Hospital, Hong Kong
Dr. Vijay Maruti Patil
Dr. Vijay Maruti Patil
P. D. Hinduja Hospital and Medical Research Centre, India
Closing
Dr. Ang Mei Kim
Dr. Ang Mei Kim
National Cancer Centre Singapore, Singapore
Please contact
[email protected]
if you have any enquiries